Format

Send to

Choose Destination
Brain Dev. 2016 Feb;38(2):209-16. doi: 10.1016/j.braindev.2015.08.003. Epub 2015 Aug 14.

Neurological outcomes in symptomatic congenital cytomegalovirus-infected infants after introduction of newborn urine screening and antiviral treatment.

Author information

1
Department of Pediatrics, Kobe University Hospital, Kobe, Japan.
2
Department of Pediatrics, Kobe University Hospital, Kobe, Japan. Electronic address: ichim@med.kobe-u.ac.jp.
3
Department of Clinical Laboratory, Kobe University Hospital, Kobe, Japan.
4
Department of Obstetrics and Gynecology, Kobe University Hospital, Kobe, Japan.
5
Department of Otolaryngology-Head and Neck Surgery, Kobe University Hospital, Kobe, Japan.
6
Department of Obstetrics, Hyogo Prefectural Kobe Children's Hospital, Kobe, Japan.
7
Nadeshiko Ladies Hospital, Kobe, Japan.
8
Department of Microbiology and Immunology, Gifu Pharmaceutical University, Gifu, Japan.

Abstract

BACKGROUND:

Newborn screening for urinary cytomegalovirus (CMV) and early introduction of antiviral treatment are expected to improve neurological outcomes in symptomatic congenital CMV-infected infants. This cohort study prospectively evaluated neurological outcomes in symptomatic congenital CMV-infected infants following the introduction of hospital-based newborn urinary CMV screening and antiviral treatment.

SUBJECTS/METHODS:

Following institutional review board approval and written informed consent from their parents, newborns were prospectively screened from 2009 to 2014 for urinary CMV-DNA by PCR within 1 week after birth at Kobe University Hospital and affiliated hospitals. CMV-positive newborns were further examined at Kobe University Hospital, and those diagnosed as symptomatic were treated with valganciclovir for 6 weeks plus immunoglobulin. Clinical neurological outcomes were evaluated at age ⩾12 months and categorized by the presence and severity of neurologic sequelae.

RESULTS:

Urine samples of 6348 newborns were screened, with 32 (0.50%) positive for CMV. Of these, 16 were diagnosed with symptomatic infection and 12 received antiviral treatment. Four infants developed severe impairment (33%), three developed mild impairment (25%), and five developed normally (42%).

CONCLUSIONS:

This is the first Japanese report of neurological assessments in infants with symptomatic congenital CMV infection who received early diagnosis and antiviral treatment. Urinary screening, resulting in early diagnosis and treatment, may yield better neurological outcomes in symptomatic congenital CMV-infected infants.

KEYWORDS:

Hospital-based study; Japanese cohort; Neurological impairment; Newborn urine screening; Valganciclovir

PMID:
26282917
DOI:
10.1016/j.braindev.2015.08.003
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center